|
The following stocks are the leading risers and fallers on AIM on Monday. ---------- AIM - WINNERS ---------- Nativo Resources PLC, up 22% at 0.61 pence, 12-month range 0.23p-2.85p. Engages Peruvian contractor Kuboc to operate the Bonanza gold mine at its wholly owned Tesoro concession in southern Peru, with mining expected to commence in February. The gold-focused mining company with interests in Peru says Kuboc mobilises an initial team next week and targets grades of 525 grams per tonne, with initial output of 5090 tonnes per month and first gold sales expected this quarter. The company plans to ramp production to 150300 tonnes per month after around three months, following preparatory works and mine-plan optimisation alongside its geologists. ---------- Andrada Mining Ltd, up 7.1% at 4.55p, 12-month range 1.78p-4.65p. Reports high-grade lithium mineralisation from surface sampling at its Lithium Ridge project, where multiple grab samples return lithium grades above 4% lithium oxide, or Li2O, peaking at 4.67% Li2O. Andrada Mining says the results validate its stage 1 drilling programme at Lithium Ridge, which is funded by partner Sociedad Quimica y Minera de Chile SA under an earn-in to acquire a 30% stake. The company confirms spodumene as the primary lithium mineral and highlights significant associated tin and tantalum mineralisation, with peak grades of 3.12% tin and 905 parts per million tantalum, pointing to polymetallic upside and potential by-product credits. Geological mapping and grab sampling identify more than 1,500 outcropping pegmatites across the licence area, extending the lithium-bearing trend to around 6 kilometres. Andrada says stage 1 drilling advances on schedule and it awaits first assay results. ---------- AIM - LOSERS ---------- Proteome Sciences PLC, down 32% at 2.2p, 12-month range 1.30p-5.40p. Launches a retail offer of up to 3.4 million shares at 1.75 pence each to raise up to £60,000, following an £840,000 fundraise completed earlier in January. The company says the retail offer is aimed at existing shareholders and will fund the conclusion of a DXT licence, expansion of mass spectrometry capacity and staffing at its San Diego facility, and further product development. The London-based life sciences company says the funding supports rising demand after securing new biopharma contracts in Europe and the US, and will also be used to introduce new isotopic tagging products and chemoproteomic workflows. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
